KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $2.2 billion.

  • CRISPR Therapeutics AG's Liabilities and Shareholders Equity fell 47.97% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 billion, marking a year-over-year decrease of 627.57%. This contributed to the annual value of $2.2 billion for FY2024, which is 55.9% up from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Liabilities and Shareholders Equity stood at $2.2 billion, which was down 47.97% from $2.0 billion recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Liabilities and Shareholders Equity peaked at $2.9 billion during Q2 2021, and registered a low of $2.0 billion during Q1 2021.
  • Its 5-year average for Liabilities and Shareholders Equity is $2.3 billion, with a median of $2.2 billion in 2025.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 17705.98% in 2021, then plummeted by 1848.99% in 2022.
  • CRISPR Therapeutics AG's Liabilities and Shareholders Equity (Quarter) stood at $2.8 billion in 2021, then decreased by 18.49% to $2.2 billion in 2022, then dropped by 0.6% to $2.2 billion in 2023, then increased by 0.56% to $2.2 billion in 2024, then rose by 0.15% to $2.2 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $2.2 billion for Q3 2025, versus $2.0 billion for Q2 2025 and $2.2 billion for Q1 2025.